Selumetinib (AZD6244) is a drug that was discovered by Array BioPharma and was licensed to AstraZeneca. It is being investigated for the treatment of various types of cancer, such as non-small cell lung cancer (NSCLC).
This is Accel Pharmtech, LLC (DUNS number: 833130128)and we welcome all customers and vendors to cooperate business with us to achieve the greatest mutual benefits!
In a sweeping success for cancer immunotherapy this year, the U.S. Food & Drug Administration approved the first two treatments that use a patient’s own genetically engineered cells to combat specific kinds of blood cancer.
Both new drugs are CAR T-cell immunotherapies, created by injecting an individual’s T cells with DNA that encodes a chimeric antigen receptor (CAR). The CAR proteins jut from the immune cells’ surfaces and direct them to seek and destroy tumor cells.
CAR-T is state of the art, and this is just the beginning.
In a deal worth up to $1.5 billion, Bayer and Loxo Oncology will jointly develop two Loxo drug candidates, larotrectinib and LOXO-195, for treating cancers caused by a rare genetic mutation.
Larotrectinib was a breakout star of the American Society for Clinical Oncology conference in June, where researchers revealed that it shrank tumors in 76% of the kids and adults in a small study. LOXO-195, currently in Phase I/II trials, is designed to treat people who develop resistance to first-generation TRK inhibitors like larotrectinib.
Now, Bayer, which some investors view as a second-tier player in oncology, will split U.S. marketing responsibilities with Loxo.
Olaparib (AZD-2281, trade name Lynparza) is an FDA-approved targeted therapy for cancer, developed by KuDOS Pharmaceuticals and later by AstraZeneca. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.
Elesclomol (INN, codenamed STA-4783) is a drug that triggers apoptosis (programmed cell death) in cancer cells. It is being developed by Synta Pharmaceuticals and GlaxoSmithKline as a chemotherapy adjuvant, and has received both fast track and orphan drug status from the U.S. Food and Drug Administration for the treatment of metastatic melanoma. CAS# 488832-69-5
If you have any problems, please feel free to contact us. ♥♥♥
Ubenimex (INN), also known more commonly as bestatin, is a competitive, reversible protease inhibitor. It is being studied for use in the treatment of acute myelocytic leukemia. Ubenimex has been found to inhibit the enzymatic degradation of oxytocin, vasopressin, enkephalins, and various other peptides and compounds. CAS# 58970-76-6 And (2S,3R)-3-Amino-2-hydroxy-4-phenylbutyric acid is the intermediate of ubenimex. CAS# 59554-14-2